Brief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
09/10/2026 13:11
BRIEF-Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial Oct 9 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:
MILESTONE PHARMACEUTICALS ANNOUNCES FIRST EUROPEAN STUDY PARTICIPANT ENROLLED IN REVERA-301 PHASE 3 CLINICAL TRIAL
Source text: ID:nGNX1pKnRw
Further company coverage: MIST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview